Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

atezolizumab 2Magnetic Resonance Spectroscopy 2tivozanib 1romidepsin 1pembrolizumab 1pasireotide 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1Specimen Handling 1Respiratory Therapy 1Quality of Life 1Patient Reported Outcome Measures 1PT-100 dipeptide 1Neuropsychological Tests 1Molecular Diagnostic Techniques 1Lactones 1Immunotherapy 1Fluorodeoxyglucose F18 1FAPI-46 1Drug Therapy 1Depsipeptides 1Cabergoline 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × tivozanib × NET × Clear all
NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡